Literature DB >> 23263848

Prognostic significance of serum miR-17-5p in lung cancer.

Qun Chen1, Qing Si, Song Xiao, Qiang Xie, Jiangping Lin, Chenhui Wang, Lizhou Chen, Qiaolin Chen, Lin Wang.   

Abstract

miR-17-5p is abnormally expressed in various tumor types. The aim of this study was to investigate the expression level of miR-17-5p in serum of patients with lung cancer and to determine whether serum miR-17-5p expression is related to the prognosis of patients with lung cancer. RT-qPCR was used to examine expression of miRNA-17-5p in 20 pairs of lung cancer and adjacent normal tissues, and sera from 221 patients with lung cancer and 54 matched controls. The correlation of serum miR-17-5p with clinicopathological factors or prognosis of patients with lung cancer was analyzed. The expression level of miR-17-5p obviously increased in lung cancer tissues (P = 0.004). Furthermore, serum miR-17-5p expression also significantly increased in patients with lung cancer compared with healthy individuals (P = 0.03). The survival analysis showed that serum miR-17-5p expression was closely related to the survival of patients with lung cancer. Patients with high miR-17-5p expression had shorter survival times [hazard ratio (HR) = 1.767, 95 %CI 1.039-3.005, P = 0.035]. A lower expression level of serum miR-17-5p helps extend the survival of patients with lung cancer. Thus, miR-17-5p may be potential biomarker for prediction the prognosis in patients with lung cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23263848     DOI: 10.1007/s12032-012-0353-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.

Authors:  Vassiliki Papadimitrakopoulou
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

Review 3.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

4.  Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer.

Authors:  Niels H H Heegaard; Aaron J Schetter; Judith A Welsh; Mitsuhiro Yoneda; Elise D Bowman; Curtis C Harris
Journal:  Int J Cancer       Date:  2011-08-26       Impact factor: 7.396

Review 5.  Screening for lung cancer.

Authors:  R L Manser; L B Irving; C Stone; G Byrnes; M Abramson; D Campbell
Journal:  Cochrane Database Syst Rev       Date:  2004

6.  MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc.

Authors:  Baltazar D Aguda; Yangjin Kim; Melissa G Piper-Hunter; Avner Friedman; Clay B Marsh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-09       Impact factor: 11.205

7.  miR-17-5p as a novel prognostic marker for hepatocellular carcinoma.

Authors:  Ling Chen; Meng Jiang; Weijie Yuan; Huihuan Tang
Journal:  J Invest Surg       Date:  2012-06       Impact factor: 2.533

8.  Computed tomography screening and lung cancer outcomes.

Authors:  Peter B Bach; James R Jett; Ugo Pastorino; Melvyn S Tockman; Stephen J Swensen; Colin B Begg
Journal:  JAMA       Date:  2007-03-07       Impact factor: 56.272

9.  Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer.

Authors:  Mei Wang; Hongbing Gu; Sheng Wang; Hui Qian; Wei Zhu; Ling Zhang; Chonghui Zhao; Yang Tao; Wenrong Xu
Journal:  Mol Med Rep       Date:  2012-03-08       Impact factor: 2.952

10.  MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression.

Authors:  B Diosdado; M A van de Wiel; J S Terhaar Sive Droste; S Mongera; C Postma; W J H J Meijerink; B Carvalho; G A Meijer
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more
  42 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

2.  Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer.

Authors:  Hong Yu; Hui Li; Hua Qian; Xia Jiao; Xiaowei Zhu; Xiaoqin Jiang; Guihong Dai; Junxing Huang
Journal:  Med Oncol       Date:  2014-10-14       Impact factor: 3.064

3.  Single nucleotide polymorphisms of cathepsin S and the risks of asthma attack induced by acaroid mites.

Authors:  Chaopin Li; Qi Chen; Yuxin Jiang; Zhiming Liu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  The oncogenic and prognostic potential of eight microRNAs identified by a synergetic regulatory network approach in lung cancer.

Authors:  Ramkrishna Mitra; Zhongming Zhao
Journal:  Int J Comput Biol Drug Des       Date:  2014-12-25

Review 5.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

6.  Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer.

Authors:  Hong Yu; Guangzhong Gao; Lin Jiang; Lingchuan Guo; Mei Lin; Xiao Jiao; Weiguang Jia; Junxing Huang
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

7.  Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis.

Authors:  Menha Swellam; Noha M Bakr; Hekmat M El Magdoub; Marwa S Hamza; Lobna R Ezz El Arab
Journal:  J Mol Neurosci       Date:  2020-09-28       Impact factor: 3.444

8.  MicroRNAs as Novel Biomarkers of Deployment Status and Exposure to Polychlorinated Dibenzo-p-Dioxins/Dibenzofurans.

Authors:  Collynn F Woeller; Thomas H Thatcher; Daniel Van Twisk; Stephen J Pollock; Amanda Croasdell; Philip K Hopke; Xiaoyan Xia; Juilee Thakar; Patricia J Sime; Timothy M Mallon; Mark J Utell; Richard P Phipps
Journal:  J Occup Environ Med       Date:  2016-08       Impact factor: 2.162

9.  Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy.

Authors:  Hong Yu; Bensong Duan; Lin Jiang; Mei Lin; Haihui Sheng; Junxing Huang; Hengjun Gao
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

10.  miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome.

Authors:  D Petriella; S De Summa; R Lacalamita; D Galetta; A Catino; A F Logroscino; O Palumbo; M Carella; F A Zito; G Simone; S Tommasi
Journal:  Tumour Biol       Date:  2015-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.